ArticlePathogens and disease2025
Akkermansia muciniphila attenuates sepsis-induced immunosuppression by shaping endotoxin-tolerant macrophage phenotypes.
Article in Pathogens and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a life-threatening condition characterized by immunosuppression, largely mediated by endotoxin tolerance. Akkermansia muciniphila (AKK), a gut probiotic, has been shown to modulate immune responses. In this study, 16S rRNA sequencing revealed decreased AKK levels in immunosuppressed individuals. In vitro experiments using RAW 264.7 macrophages demonstrated that endotoxin tolerance induced an M2 phenotype, which was reversed by AKK treatment, promoting an M1 phenotype. Additionally, AKK enhanced bacterial clearance of Pseudomonas aeruginosa. In vivo, AKK administration alleviated immunosuppression in an endotoxin-tolerant mouse model by modulating macrophage phenotypes. These findings highlight AKK as a potential therapeutic candidate for sepsis-induced immunosuppression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.